User menu

Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.

Bibliographic reference Hermans, Michel. Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.. In: Diabetes and Vascular Disease Research, Vol. 8, no.3, p. 180-189 (2011)
Permanent URL http://hdl.handle.net/2078.1/132380
  1. Stratton I. M, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, 10.1136/bmj.321.7258.405
  2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), 10.1016/s0140-6736(98)07019-6
  3. UK Prospective Diabetes Study Group., UK Prospective Diabetes Study Group. BMJ, 317, 703 (1998)
  4. , Standards of Medical Care in Diabetes--2010, 10.2337/dc10-s011
  5. IDF Clinical Guidelines Task Force., Global guideline for Type 2 diabetes (2005)
  6. Hippisley-Cox Julia, Pringle M, Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey, 10.1016/s0140-6736(04)16765-2
  7. Ayad F., Belhadj M., Pariés J., Attali J. R., Valensi P., Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications : Cardiac autonomic neuropathy and hypertension, 10.1111/j.1464-5491.2010.03027.x
  8. National Cholesterol Education Program., Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2010)
  9. Task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: full text. http://www.escardio.org (accessed November 2010).
  10. Abdul-Ghani M., Isr Med Assoc J, 8, 378 (2006)
  11. Hermans Michel P., Amoussou-Guenou K. Daniel, Ahn Sylvie A., Rousseau Michel F., Impact of metabolic syndrome and its severity on microvascular complications in type 2 diabetes, 10.1016/j.dsx.2010.05.021
  12. Ismail-Beigi Faramarz, Craven Timothy, Banerji Mary Ann, Basile Jan, Calles Jorge, Cohen Robert M, Cuddihy Robert, Cushman William C, Genuth Saul, Grimm Richard H, Hamilton Bruce P, Hoogwerf Byron, Karl Diane, Katz Lois, Krikorian Armand, O'Connor Patrick, Pop-Busui Rodica, Schubart Ulrich, Simmons Debra, Taylor Harris, Thomas Abraham, Weiss Daniel, Hramiak Irene, Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial, 10.1016/s0140-6736(10)60576-4
  13. , Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes, 10.1056/nejmoa1001288
  14. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes, 10.1056/nejmoa0802987
  15. Zoungas S., de Galan B. E., Ninomiya T., Grobbee D., Hamet P., Heller S., MacMahon S., Marre M., Neal B., Patel A., Woodward M., Chalmers J., , Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes: New results from the ADVANCE trial, 10.2337/dc09-0959
  16. Duckworth William, Abraira Carlos, Moritz Thomas, Reda Domenic, Emanuele Nicholas, Reaven Peter D., Zieve Franklin J., Marks Jennifer, Davis Stephen N., Hayward Rodney, Warren Stuart R., Goldman Steven, McCarren Madeline, Vitek Mary Ellen, Henderson William G., Huang Grant D., Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes, 10.1056/nejmoa0808431
  17. Gæde Peter, Vedel Pernille, Larsen Nicolai, Jensen Gunnar V.H., Parving Hans-Henrik, Pedersen Oluf, Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes, 10.1056/nejmoa021778
  18. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, 10.1016/s0140-6736(05)67667-2
  19. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TME, Moffitt MS, Taskinen M-R, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG, Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial, 10.1016/s0140-6736(07)61607-9
  20. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus, 10.1056/nejmoa1001282
  21. Effects of Intensive Glucose Lowering in Type 2 Diabetes, 10.1056/nejmoa0802743
  22. Scott R., O'Brien R., Fulcher G., Pardy C., d'Emden M., Tse D., Taskinen M.-R., Ehnholm C., Keech A., , Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, 10.2337/dc08-1543
  23. Burgess D. C., Hunt D., Li L., Zannino D., Williamson E., Davis T. M.E., Laakso M., Kesaniemi Y. A., Zhang J., Sy R. W., Lehto S., Mann S., Keech A. C., Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, 10.1093/eurheartj/ehp377
  24. Rajamani Kushwin, Colman Peter G, Li Li Ping, Best James D, Voysey Merryn, D'Emden Michael C, Laakso Markku, Baker John R, Keech Anthony C, Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial, 10.1016/s0140-6736(09)60698-x
  25. Forsblom C., Hiukka A., Leinonen E. S., Sundvall J., Groop P. H., Taskinen M. R., Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy, 10.2337/dc09-0621
  26. Davis T. M. E., , Ting R., Best J. D., Donoghoe M. W., Drury P. L., Sullivan D. R., Jenkins A. J., O’Connell R. L., Whiting M. J., Glasziou P. P., Simes R. J., Kesäniemi Y. A., Gebski V. J., Scott R. S., Keech A. C., Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study, 10.1007/s00125-010-1951-1
  27. Genest Jacques, Frohlich Jiri, Steiner George, Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus, 10.1016/j.amjcard.2003.12.022
  28. TriCor® (fenofibrate) tablets. Prescribing information (Abbott Inc.) (2010)
  29. Levey Andrew S., Cattran Daniel, Friedman Aaron, Miller W. Greg, Sedor John, Tuttle Katherine, Kasiske Bertram, Hostetter Thomas, Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration, 10.1053/j.ajkd.2009.04.029
  30. Burgos-Calderon Rafael, Depine Santos, Systematic approach for the management of chronic kidney disease: moving beyond chronic kidney disease classification : , 10.1097/mnh.0b013e32833281dc
  31. Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease : The Bezafibrate Infarction Prevention (BIP) Study, 10.1161/01.cir.102.1.21
  32. Manninen Vesa, Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study, 10.1001/jama.1988.03410050061031
  33. Robins Sander J., Collins Dorothea, Wittes Janet T., Papademetriou Vasilios, Deedwania Prakash C., Schaefer Ernst J., McNamara Judith R., Kashyap Moti L., Hershman Jerome M., Wexler Laura F., Rubins Hanna Bloomfield, for the VA-HIT Study Group, Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events : VA-HIT: A Randomized Controlled Trial, 10.1001/jama.285.12.1585
  34. Haak T., Eur J Med Res, 3, 50 (1998)
  35. Otsuki M., Vasc Health Risk Manag, 1, 209 (2005)
  36. Fegan P. G., Shore A. C., Mawson D., Tooke J. E., MacLeod K. M., Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy, 10.1111/j.1464-5491.2005.01719.x
  37. Undas A., Thromb Haemost, 94, 193 (2005)
  38. Tomizawa A., Metabolism (2010)
  39. Kim Jaetaek, Ahn Ji-Hyun, Kim Jeong-Hun, Yu Young-Suk, Kim Ho-Shik, Ha Joohun, Shinn Soon-Hyun, Oh Yeon-Sahng, Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway, 10.1016/j.exer.2007.01.009
  40. Scoditti Egeria, Massaro Marika, Carluccio Maria Annunziata, Distante Alessandro, Storelli Carlo, De Caterina Raffaele, PPARγ agonists inhibit angiogenesis by suppressing PKCα- and CREB-mediated COX-2 expression in the human endothelium, 10.1093/cvr/cvp400
  41. Grau Raquel, Díaz-Muñoz Manuel D., Cacheiro-Llaguno Cristina, Fresno Manuel, Iñiguez Miguel A., Role of Peroxisome Proliferator-Activated Receptor Alpha in the Control of Cyclooxygenase 2 and Vascular Endothelial Growth Factor: Involvement in Tumor Growth, 10.1155/2008/352437
  42. Meissner M., PPAR  Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation, 10.1161/01.res.0000113781.08139.81
  43. Cheung Ning, Wong TY, Fenofibrate and diabetic retinopathy, 10.1016/s0140-6736(08)60333-5